These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 30066852)

  • 1. Upregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling.
    Lucas J; Hsieh TC; Halicka HD; Darzynkiewicz Z; Wu JM
    Int J Oncol; 2018 Oct; 53(4):1469-1480. PubMed ID: 30066852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
    Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
    Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
    Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
    Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
    Li CJ; Lin LT; Hou MF; Chu PY
    Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy induces enrichment of CD47
    Samanta D; Park Y; Ni X; Li H; Zahnow CA; Gabrielson E; Pan F; Semenza GL
    Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1239-E1248. PubMed ID: 29367423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.
    Li H; Li CW; Li X; Ding Q; Guo L; Liu S; Liu C; Lai CC; Hsu JM; Dong Q; Xia W; Hsu JL; Yamaguchi H; Du Y; Lai YJ; Sun X; Koller PB; Ye Q; Hung MC
    Gastroenterology; 2019 May; 156(6):1849-1861.e13. PubMed ID: 30711629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses.
    Tian H; Kang Y; Song X; Xu Y; Chen H; Gong X; Zhang W; Xu Y; Xia X; Gao X; Yao W
    Cancer Lett; 2020 Apr; 476():170-182. PubMed ID: 32092355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PERK-Phosphorylated eIF2α Pathway Suppresses Tumor Metastasis Through Downregulating Expression of Programmed Death Ligand 1 and CXCL5 in Triple-Negative Breast Cancer.
    Zou W; Bai Y; Wang X; Cheng K; Sun H; Zhang G; Wang X; Yang Z
    Cancer Biother Radiopharm; 2017 Oct; 32(8):282-287. PubMed ID: 29053414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lippia origanoides extract induces cell cycle arrest and apoptosis and suppresses NF-κB signaling in triple-negative breast cancer cells.
    Raman V; Fuentes Lorenzo JL; Stashenko EE; Levy M; Levy MM; Camarillo IG
    Int J Oncol; 2017 Dec; 51(6):1801-1808. PubMed ID: 29075784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
    El Guerrab A; Bamdad M; Kwiatkowski F; Bignon YJ; Penault-Llorca F; Aubel C
    Oncotarget; 2016 Nov; 7(45):73618-73637. PubMed ID: 27655662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor PD-L1 Induction by Resveratrol/Piceatannol May Function as a Search, Enhance, and Engage ("SEE") Signal to Facilitate the Elimination of "Cold, Non-Responsive" Low PD-L1-Expressing Tumors by PD-L1 Blockade.
    Hsieh TC; Wu JM
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31783532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer.
    Kala R; Shah HN; Martin SL; Tollefsbol TO
    BMC Cancer; 2015 Oct; 15():672. PubMed ID: 26459286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
    Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
    Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a.
    Huang X; Xie X; Wang H; Xiao X; Yang L; Tian Z; Guo X; Zhang L; Tang H; Xie X
    J Exp Clin Cancer Res; 2017 Sep; 36(1):129. PubMed ID: 28915924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical significance of PD‑L1 in colorectal cancer (Review).
    Ntomi V; Foukas P; Papaconstantinou D; Antonopoulou I; Pikoulis A; Panagiotides I; Pikoulis E; Syrigos K
    Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
    Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
    Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
    Manjarrez-Orduño N; Menard LC; Kansal S; Fischer P; Kakrecha B; Jiang C; Cunningham M; Greenawalt D; Patel V; Yang M; Golhar R; Carman JA; Lezhnin S; Dai H; Kayne PS; Suchard SJ; Bernstein SH; Nadler SG
    Front Immunol; 2018; 9():1613. PubMed ID: 30123214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer.
    Nakayama Y; Mimura K; Tamaki T; Shiraishi K; Kua LF; Koh V; Ohmori M; Kimura A; Inoue S; Okayama H; Suzuki Y; Nakazawa T; Ichikawa D; Kono K
    Int J Oncol; 2019 Jun; 54(6):2030-2038. PubMed ID: 31081058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.